Related Experiment Video
Updated: Jul 8, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?
Cristiano Ferlini1, Giuseppina Raspaglio, Lucia Cicchillitti
1Laboratory of Antineoplastic Pharmacology, Catholic University of the Sacred Heart, Rome, Italy. cferlini@rm.unicatt.it
Abstract:
Vinca alkaloids and taxanes represent the mainstay of medical treatment of hematological and solid tumors. Unfortunately, a major clinical problem with these agents is drug resistance. Although a plethora of mechanisms of drug resistance have been described, only a few of them have been validated in clinical trials. Among these, the one involving the protein TUBB3 seems to represent a promising target for studying drug resistance. In fact, it seems that this protein is a factor promoting cell survival and represents an endogenous element of an inherent drug-resistance program built into cells to counteract the activity of microtubule-interacting drugs. Its pivotal role has been ascertained in clinical trials in lung, breast, and ovarian cancer, three diseases that can be successfully treated with microtubule-interacting drugs. Although TUBB3 is probably not a unique factor in drug resistance, the hope is that direct targeting of this protein will increase the response to microtubule-interacting drugs, thereby overcoming an important element in the growth of drug resistance.
Insights
Drug resistance to vinca alkaloids and taxanes is a major challenge in cancer treatment. Targeting the TUBB3 protein shows promise in overcoming this resistance in lung, breast, and ovarian cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Vinca alkaloids and taxanes are primary treatments for hematological and solid tumors.
- Drug resistance significantly limits the clinical efficacy of these microtubule-interacting agents.
- TUBB3 protein is implicated as a key factor in inherent drug resistance mechanisms.
Purpose of the Study:
- To investigate the role of TUBB3 protein in mediating resistance to microtubule-interacting drugs.
- To explore TUBB3 as a potential therapeutic target for overcoming drug resistance in cancer.
Main Methods:
- Clinical trial validation of drug resistance mechanisms.
- Analysis of TUBB3 protein expression and function in cancer cells.
- Evaluation of therapeutic strategies targeting TUBB3.
Main Results:
- TUBB3 protein has been validated in clinical trials as a resistance factor in lung, breast, and ovarian cancers.
- TUBB3 appears to promote cancer cell survival and counteract microtubule-interacting drug activity.
- Its role is confirmed in diseases treatable with these drugs.
Conclusions:
- TUBB3 protein is a significant factor in cancer drug resistance.
- Targeting TUBB3 offers a promising strategy to enhance patient response to microtubule-interacting drugs.
- Overcoming TUBB3-mediated resistance could improve treatment outcomes for various cancers.
More Related Videos
07:21Quantitative Microtubule Fractionation Technique to Separate Stable Microtubules, Labile Microtubules, and Free Tubulin in Mouse Tissues
Published on: November 17, 2023
07:54Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles
Published on: November 5, 2020
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Destabilization of Microtubules
Microtubule Instability
Microtubule Instability
Microtubule Formation